title: Inhibition of monoamine oxidase within monoaminergic neurons in the rat brain by (E)-beta-fluoromethylene-m-tyrosine (MDL 72394).
abstract: The irreversible inhibition of the monoamine oxidase (MAO) activity within monoaminergic neurons in the rat brain 24 h after single or repeated administration of (E)-beta-fluoromethylene-m-tyrosine (FMMT, MDL 72394) was examined. The enzyme activity was determined by incubating synaptosome-rich homogenates of hypothalamus or striatum with low concentrations of 5-[14C]hydroxytryptamine (5-HT), [14C]noradrenaline (NA), or [14C]dopamine (DA) in the absence and presence of the selective amine uptake inhibitors citalopram (5-HT), maprotiline (NA), and GBR 12909 (DA). After a single subcutaneous injection of FMMT, the inhibition of MAO within the noradrenergic and dopaminergic neurons was significant but only slightly greater than that outside these neurons. The opposite relationship was observed for the serotonergic neurons. After 7 days' treatment of rats with carbidopa, 20 mg/kg p.o., + FMMT once daily, the preference for the inhibition of MAO within the noradrenergic and dopaminergic neurons was accentuated further. The inhibition outside the serotonergic neurons was still greater than within these neurons. The NA uptake inhibitor CPP 199 antagonized the selective inhibition of MAO within the noradrenergic neurons, which indicates that this preference is due to the accumulation of the active metabolite (E)-beta-fluoromethylene-m-tyramine by the NA transporter.
authors.affiliation: Department of Neuropharmacology, Astra Alab AB, Södertälje, Sweden.
authors.forename: I
authors.initials: I
authors.lastname: Fagervall
authors.forename: S B
authors.initials: SB
authors.lastname: Ross
mesh_terms: D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D002230:Carbidopa / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D007031:Hypothalamus / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors; D009474:Neurons / Q000187:drug effects / Q000201:enzymology*; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism; D013574:Synaptosomes / Q000201:enzymology; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015031:Zimeldine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D015306:Biogenic Monoamines; D018492:Dopamine Antagonists; D008996:Monoamine Oxidase Inhibitors; D010879:Piperazines; D012701:Serotonin; D015031:Zimeldine; D014443:Tyrosine; C017578:norzimelidine; C043425:vanoxerine; C046880:beta-fluoromethylene-3-tyrosine; D008995:Monoamine Oxidase; D002230:Carbidopa; D004298:Dopamine; D009638:Norepinephrine